Short answer
Neuronetics, Inc. (STIM) filed an 8-K current report with the SEC on May 5, 2026 reporting Item 2.02 (Results of Operations and Financial Condition), Item 7.01 (Regulation FD Disclosure), Item EX-99.1 (Exhibit EX-99.2). Q1 2026 results for three months ended March 31, 2026, released May 5, 2026.
Neuronetics, Inc. 8-K event analysis
AI summary of each reported item and its exhibits
Item 2.02 · Results of Operations and Financial Condition
- Q1 2026 results for three months ended March 31, 2026, released May 5, 2026
- Full financial results and management commentary available in Exhibit 99.1 press release
- Earnings disclosure furnished under Item 2.02, not incorporated as a filing for liability purposes
Item 7.01 · Regulation FD Disclosure
- Reg FD disclosure covers Neuronetics’ fiscal 2026 outlook, including revenue, expenses, growth, and upcoming-quarter expectations
- Outlook remains exposed to execution risk, operating losses, reimbursement availability, physician demand, and competing therapies
- Greenbrook TMS transaction introduces potential business-relationship effects and integration-related uncertainty
- Credit-facility terms and ability to achieve positive cash flow remain material financial risks
Item EX-99.1 · Exhibit EX-99.2
- Q1 revenue $34.5M, up 8%, led by U.S. clinic revenue growth of 15% to $21.5M
- Operating expenses fell 6% to $25.1M, narrowing net loss to $10.8M from $12.7M
- Gross margin declined to 46.9% from 49.2%, signaling unfavorable business mix despite operating-cost reductions
- Cash and restricted cash fell to $19.0M after $9.4M operating cash burn and a $5.0M debt repayment
- 2026 outlook maintained: revenue $160M-$166M, gross margin 47%-49%, operating cash flow negative $13M-$17M
Generated from the filing text and exhibits; verify against the original. What 8-K item codes mean
Other Neuronetics, Inc. 8-K filings
Get the next STIM 8-K as it lands
Follow STIM for push alerts, or ask the research agent what this filing means.